Tag: opioid epidemic

Dem House candidate pushes tough on fentanyl stance after dismissing it as border issue

Democratic congressional candidate Monica Tranel appears to be changing her tune on the fentanyl crisis this cycle after previously suggesting that the deadly drug was not coming from the southern border.

Tranel, the Democratic candidate running in Montana’s First Congressional District against Republican incumbent Rep. Ryan Zinke, recently released a campaign ad appearing tough on the border.

However, during her first congressional bid in 2022, Tranel claimed that the border crisis is unrelated to fentanyl trafficking while debating Zinke at the City Club Missoula.

“It is a significant issue where we are, but where it is coming from is not the southern border,” Tranel said of fentanyl during the debate. “It’s being made in China, and how it’s getting here is a complex series of things that are happening, and shutting down the border is not going to reduce the fentanyl crisis.”

Keep reading

Medical Marijuana Helps People With Arthritis And Other Rheumatic Conditions Reduce Use Of Opioids And Other Medications, Study Shows

New research on the use of medical marijuana among people with rheumatic conditions such as arthritis finds that more than 6 in 10 patients who used medical cannabis reported substituting it for other medications, including NSAIDs, opioids, sleep aids and muscle relaxants. Most patients further said that the use of marijuana allowed them to reduce or stop using those medications entirely.

“The primary reasons for substitution were fewer adverse effects, better symptom management, and concerns about withdrawal symptoms,” says the study, published this month by the American College of Rheumatology. “Substitution was associated with THC use and significantly higher symptom improvements (including pain, sleep, anxiety, and joint stiffness) than nonsubstitution.”

The findings, say authors at the University of Michigan Medical School, McGill University and the University of Buffalo, “suggest that an appreciable number of people with rheumatic diseases substitute medications with [medical cannabis] for symptom management.”

Data for the study came from an online, anonymous survey of adult residents of the United States and Canada, which was advertised on social media and through email contact lists of the Arthritis Foundation and Arthritis Society Canada. Of 1,727 completed surveys, 763 respondents said they currently used cannabis, while 655 said they’d never used marijuana and 268 said they’d used but since discontinued. Researchers analyzed responses of only those who said they were current cannabis users.

“Among 763 participants, 62.5% reported substituting MC products for medications, including nonsteroidal anti-inflammatory drugs (54.7%), opioids (48.6%), sleep aids (29.6%), and muscle relaxants (25.2%),” the report says.

Keep reading

How the Opiate Conspiracy Widened

Many businesses will gleefully sell you a harmful addiction.

The tobacco industry was supposedly subdued decades ago by a historic legal beat-down, yet somehow spends $22 million every day promoting its wares. That’s nearly a million dollars an hour. Websites for kids sport vaping ads. “Cigfluencers” work the podcasts. And movies are smoke-choked like never before.

There was a time when a cigarette company could pay a mere $43,000 for Superman to be thrown into a Marlboro truck by the evil General Zod in front of Marlboro-smoker Lois Lane. (She had never smoked in the comic books, by the way.)

These days, modern Hollywood supposedly disdains tobacco cash. Yet somehow the movies remain one long, glamorous advertisement for cigarettes. Of this year’s ten Oscar Best Picture nominees, nine featured seductive and edgy smoking. (Only “Barbie” did not.)

The marketeers assure us we’ll be inhaling happiness and hipness. Maybe so, but there are also those hot, lung-damaging fumes — a reality that eventually catches up and kills about half a million of us every year.

(Brief digression: COVID-19 had a U.S. death toll of about 1.2 million over three tough years. Many COVID-19 victims were also smokers, so it’s hard to compare the pandemic and smoking death tolls. That said, we can certainly compare the public health responses. When COVID-19 arrived, we shut down the entire planet, and the virus would go on to kill an average of 400,000 Americans a year for three years. Smoking has been here all along — glamorized, marketed to kids — cheerfully killing 500,000 Americans a year, every year, forever.)

Keep reading

Psychedelics Have ‘Demonstrated Potential For Treating Drug Addiction’ And Alcoholism, New Research Shows

Two new studies on psychedelics and alcoholism—including one with contributions from a top federal drug official—offer hope for new ways to treat alcohol use disorder (AUD).

One says a single dose of psilocybin “was safe and effective in reducing alcohol consumption in AUD patients,” while the other concludes that classic psychedelics like psilocybin and LSD “have demonstrated potential for treating drug addiction, especially AUD.”

The first study looked at 10 treatment-seeking adults “with severe AUD,” according to a preprint version of the research published online at Research Square. After a single 25 milligram dose of psilocybin, “alcohol consumption significantly decreased” during a 12-week period, the team found.

Coauthored by National Institute on Drug Abuse (NIDA) Director Nora Volkow—in her role at the National Institute on Alcohol Abuse and Alcoholism’s neuroimaging laboratory—along with 10 researchers at the University of Copenhagen, in Denmark, the open-label study found that most participants craved alcohol less and consumed fewer drinks following treatment with psilocybin.

“Participants reported a decrease from baseline to week 1 in alcohol craving,” the paper says—a decrease that was sustained four weeks and 12 weeks after the psychedelic was administered. “Further, participants reported an immediate change from baseline to week 1 in self-efficacy, i.e. confidence in the ability to abstain from alcohol.”

Keep reading

Cannabis Is More Effective In Treating Musculoskeletal Pain Than Traditional Medications Are, Patients Say In New Study

More than 1 in 5 patients who go to orthopedic surgeons with chronic musculoskeletal pain are using or have used some form of cannabis to manage their pain, according to a new study published this month. Of those, almost two thirds said they felt cannabis was very or somewhat effective, while more than 9 in 10 said it was at least slightly effective.

“More than half (57%) claimed cannabis to be more effective than other analgesic medications, and 40% reported decreasing their use of other analgesic medications since starting cannabis use,” the research found, adding that only 26 percent reported a doctor recommended cannabinoids to them to treat their musculoskeletal (MSK) pain.

Notably, among those who said they used cannabis to manage pain, the most commonly used cannabinoid was CBD (39 percent), followed by a hybrid of multiple cannabinoids (20 percent). Almost a quarter (23 percent) said they were unaware of their cannabis’s composition.

Further, among patients who were not cannabis users, roughly two thirds (65 percent) said they were interested in using marijuana to manage their pain but reported barriers to use such as “lack of knowledge regarding access, use and evidence, and stigma,” although stigma was, contrary to previous research, not a primary concern.

Keep reading

Kentucky Governor Pushes DEA To Reschedule Marijuana, Saying It’s An “Alternative To Deadly Opioids’

The governor of Kentucky has added his voice to the chorus of people urging the Drug Enforcement Administration (DEA) to follow through on the Biden administration’s plan to reschedule marijuana.

Gov. Andy Beshear (D) on Wednesday submitted a public comment on the proposed rule, which would move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). There are currently more than 31,000 comments submitted on the proposal, with the deadline to weigh in coming up on Monday.

“As Governor, my job is to move our state forward,” Beshear said, referencing his state’s medical cannabis legalization policy that he signed into law. “Rescheduling marijuana to Schedule III is a significant, common-sense step forward for all Kentuckians, especially those with significant medical conditions.”

He added that the reclassification will have “substantial and meaningful impacts” on patients, communities, businesses and research.

While he argued that the reform would provide an “alternative to deadly opioids,” that’s not necessarily the case. As a Schedule III drug, marijuana would still be federally illegal unless the Food and Drug Administration (FDA) approved it as a medicine, which is unlikely for a botanical substance.

Beshear added that rescheduling will promote “fair markets” for cannabis, as it will allow state-licensed marijuana businesses to take federal tax deductions that they’ve been barred from under an Internal Revenue Service code known as 280E. The policy change would also mean “real opportunities for research on marijuana” since certain barriers imposed on studying Schedule I drugs would be lifted.

Keep reading

Legalizing And Regulating Drugs Is The Only Way Out Of The Overdose Crisis

Should heroin and cocaine be legally available to people who need and want them? If we are serious about stopping the crisis of drug overdose deaths, that is exactly the kind of profound change we need. Yes, extensive regulations would be necessary. In fact, the whole point of regulating drug production and sales is that we can better control what is being sold and to whom.

After British Columbia’s Provincial Health Officer Dr. Bonnie Henry testified to the all-party health committee in Ottawa in May that regulating these controlled drugs would minimize harms, B.C. Premier David Eby said he disagreed. He is quoted saying that “in a reality-based, real-world level, (it) doesn’t make any sense.” But does our current approach of drug prohibition “make sense?”

Since the overdose crisis was declared in 2016, illicit drug toxicity deaths have become the leading cause of unnatural death in B.C. and the leading cause of death from all causes for those aged 10 to 59. More than 44,000 people have died from drug poisoning in Canada since 2016, and more than one-third of those were in B.C. An average of 22 people are dying every day in Canada because the illicit supply of drugs is toxic.

Keep reading

Clarence Thomas appears open to making drug addiction illegal

U.S. Supreme Court justice Clarence Thomas identified a previous ruling that he would like to upend.

The conservative majority sided with an Oregon city that prohibited unhoused people from sleeping on public land, and Thomas said in his opinion in the case that he would like to “dispose” of a 1962 ruling that struck down a California law that criminalized being addicted to narcotics, reported Newsweek.

“In an appropriate case, the Court should certainly correct this error,” Thomas wrote.

The court relied on that decades-old ruling in Robinson v. California to decide that penalizing homeless people for sleeping on the streets when no other shelter was available did not violate the Eighth Amendment prohibition on cruel and unusual punishment.

Keep reading

Afghan heroin shortage could lead to more overdose deaths – UN

The Taliban’s crackdown on poppy cultivation in Afghanistan  could trigger a spike in overdose deaths if the global heroin lack is filled by more potent synthetic compounds, the UN has warned.

A report released on Wednesday by the UN Office on Drugs and Crime (UNODC) assessed the impact of a ban on opium cultivation, production, processing and trade which the Taliban reintroduced in April 2022. It came too late to affect the harvest that year, but the crackdown caused output to shrink 95% in 2023, it said.

The loss of this supply from Afghanistan, previously the world’s dominant producer of opium and heroin, was partially compensated by Myanmar, where there was a 36% increase in output. Nevertheless, global opium production fell by 74% last year, according to UN research.

Prices of opiates in Afghanistan skyrocketed last year, but the availability of old stockpiles meant that no real shortage was reported in destination markets until early 2024, the report said.

Preliminary field observations indicate that this year the supply may slightly increase, but Afghanistan is unlikely to “reach the very high production observed in the years before 2023.” If the crunch continues, the purity of heroin on the global market may decline, and the demand for substitute opiates will surge, UNODC has predicted.

Keep reading

If Opiates Are Killing Americans, Why Won’t the FDA Let Us Try an Alternative?

For more than a decade, patients who’ve needed certain controlled medications have suffered from ill-advised, untenable policies the U.S. government has instituted, allegedly to mitigate the ever-surging numbers of drug overdose deaths. These policies have been a dismal failure on multiple fronts: Not only have deaths continued to surge, but the terrifying intrusion of the Drug Enforcement Administration (DEA) into the practice of medicine has had a chilling effect on patients and their physicians. 

As the DEA relentlessly tightens production quotas on medications for pain and ADHD, it has begun tracking every pill, making doctors increasingly reluctant to prescribe any controlled drugs and leaving many patients in a lurch. Perhaps worse, DEA production quotas have caused the back-order of multiple drugs—an increasingly common burden for patients, even those fortunate to have doctors willing to risk a DEA drug bust for simply doing their job.

The ill and disabled suffer the most. Virtually all patients who have diseases or chronic pain conditions will say that the emergency department is the single worst place to go for relief from severe pain. Doctors and hospitals are often more concerned about law enforcement looking over their shoulders than patient care. Patients desperate for pain relief often turn to street drugs, where they fall victim to counterfeit pills that contain fentanyl (or worse) instead of a legal opioid. 

By contrast, doctors in Australia, Canada, the United Kingdom, and throughout Europe have been using a fixed-dose, inhaled general anesthesia medicine that effectively reduces acute pain—a medication denied to Americans by a seemingly indifferent Food and Drug Administration (FDA). 

Doctors commonly used methoxyflurane (Penthrane) as a general anesthetic in the 1960s and 1970s. But, because it had toxic effects on the liver and kidneys, anesthesiologists gradually stopped using it and turned to safer anesthetics. In 2005, the FDA removed methoxyflurane from the market.

However, an Australian company, Medical Developments International, has been marketing a lower-dose, self-administered, single-use nasal inhaler version of methoxyflurane for 30 years. Its brand name is Penthrox, though many people refer to it as the “green whistle,” because of the package it comes in. People living in Europe have had access to the green whistle since 2015, and Canadian patients have had it since 2018. 

In 2020, a randomized controlled clinical trial in the U.K. demonstrated that the drug saved an average of 71 minutes in providing pain relief to accident and emergency department patients. Likewise, a 2020 Australian trial found that a methoxyflurane inhaler “was associated with clinically significant lower pain scores compared to standard therapy.” While it may cause drowsiness in some people, methoxyflurane at this low dose has few adverse effects, such as liver and kidney toxicity, and there are no reported cases of addiction or abuse. 

In 2022, the FDA finally lifted its “clinical hold” on methoxyflurane nasal inhalers and has allowed its manufacturer to resume FDA-supervised clinical trials. Unfortunately, this is an unnecessary waste of time.

Keep reading